SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · Inovio Pharmaceuticals announced FDA accelerated approval of VOCERYQ…

INOVIO PHARMACEUTICALS, INC. · 8-K filed Nov 2, 2026 at 07:15 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 2, 2026 at 07:15 ET

Inovio Pharmaceuticals announced FDA accelerated approval of VOCERYQ (INO-3107), the first U.S. FDA-approved DNA medicine, to reduce surgery frequency in adults with Recurrent Respiratory Papillomatosis (RRP). The approval is based on a 32-patient Phase 1/2 study where 27% of evaluable patients required no surgical intervention for 12 months post-treatment. The company expects to begin shipping in approximately 60 days with full commercial launch in Q1 2027, but continued approval is contingent on a confirmatory study with a protocol due by end of 2026.

  • FDA granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with RRP.
  • Approval based on a Phase 1/2 study (RRP-001) in 32 patients; 26 patients in the efficacy population had a median of 4.5 surgeries in the 12 months prior to treatment.
  • 7 out of 26 patients (27%, 95% CI: 12-48%) demonstrated a complete response, defined as no surgical excision of papillomas after 12 months of follow-up.
  • VOCERYQ is the first U.S. FDA-approved DNA medicine, validating Inovio's platform technology.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access